NCT05265975 (SWATCH) is a Phase 1, PHASE2 clinical trial of ATG-010 in Diffuse Large B-cell Lymphoma, sponsored by Antengene Corporation.

Who is sponsoring NCT05265975?

NCT05265975 is sponsored by Antengene Corporation.

What drugs are being tested in NCT05265975?

Interventions in NCT05265975: ATG-010, Lenalidomide, Rituximab.

What condition does NCT05265975 study?

NCT05265975 studies Diffuse Large B-cell Lymphoma, Indolent Non-Hodgkin Lymphoma.

Is NCT05265975 still recruiting?

NCT05265975 is currently terminated. Last updated 9 June 2025.

Last reviewed 2025-06-09 · How we verify

NCT05265975: SWATCH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL

Terminated Phase 1, PHASE2 Last updated 9 June 2025

What this trial tests

Phase 1, PHASE2 trial testing ATG-010 in Diffuse Large B-cell Lymphoma in 54 participants. Terminated before completion.

Timeline

7 April 2022

Primary endpoint
31 December 2024

31 December 2024

Quick facts

Lead sponsor	Antengene Corporation
Phase	Phase 1, PHASE2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	54
Start date	7 April 2022
Primary completion	31 December 2024
Estimated completion	31 December 2024
Sites	6 locations across China

Drugs / interventions tested

ATG-010 — full drug profile →
Lenalidomide — full drug profile →
Rituximab — full drug profile →

Conditions studied

Diffuse Large B-cell Lymphoma — all drugs for Diffuse Large B-cell Lymphoma →
Indolent Non-Hodgkin Lymphoma — all drugs for Indolent Non-Hodgkin Lymphoma →

Sponsor

Antengene Corporation — full company profile →

Who can join

Adults 18 to 65, any sex, with Diffuse Large B-cell Lymphoma or Indolent Non-Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Single-arm, Phase Ⅰ/Ⅱ Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of ATG-010 in Combination with Lenalidomide and Rituximab (R2) in Adult Patients with Relapsed/Refractory DLBCL and iNHL Who are Ineligible for High-dose Chemotherapy (HDC) or Autologous Stem Cell Transplant (A SCT).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Modulation of anti-tumour immunity by XPO1 inhibitors.
Fisher JG, Bartlett LG, Kashyap T, Walker CJ, et al · · 2025 · cited 2× · PMID 40291981 · DOI 10.37349/etat.2025.1002310
Prognostic and functional role of the nuclear export receptor 1 (XPO1) in gastrointestinal cancers: a potential novel target?
Sokolova V, Gruber R, Pammer LM, Kocher F, et al · · 2024 · cited 1× · PMID 39729162 · DOI 10.1007/s11033-024-10169-5

Verify or expand the search:

Other trials of ATG-010

Trials testing the same drug.

NCT04998760 — A Study to Evaluate Dual mTORC1/2 Inhibitor (ATG 008) or Selective Inhibitor of Nuclear Export Compound (ATG-010) in Com · Phase 2 · unknown
NCT03944057 — A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma · Phase 2 · completed

Other recruiting trials for Diffuse Large B-cell Lymphoma

Currently open trials in the same condition.

NCT06977711 — Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large · Phase 1 · recruiting
NCT06846463 — Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+ · Phase 2 · recruiting
NCT06870487 — A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers · Phase 1 · active not recruiting
NCT06651853 — Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL · Phase 2 · recruiting
NCT06503263 — Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL · Phase 2 · recruiting

Other Antengene Corporation trials

Trials by the same sponsor.

NCT05354362 — A Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma · Phase 1 · terminated
NCT04939142 — A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexa · Phase 3 · active not recruiting
NCT04425070 — A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy · Phase 1, PHASE2 · terminated
NCT03992339 — A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma · Phase 2 · completed
NCT03944057 — A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05265975 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Antengene Corporation
Last refreshed: 9 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05265975.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing